Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Troglitazone
Drug ID BADD_D02301
Description Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Indications and Usage For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.
Marketing Status Discontinued
ATC Code A10BG01
DrugBank ID DB00197
KEGG ID D00395
MeSH ID D000077288
PubChem ID 5591
TTD Drug ID D06XZW
NDC Product Code Not Available
Synonyms Troglitazone | 5-(4-((6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione) - T | CS 045 | CS-045 | CS045 | Rezulin | Prelay
Chemical Information
Molecular Formula C24H27NO5S
CAS Registry Number 97322-87-7
SMILES CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Drug dependenceSolute carrier family 2, facilitated glucose transporter member 4P14672T676588817100; 11334413; 7744225
Drug dependenceSolute carrier family 2, facilitated glucose transporter member 1P11166T894588817100; 11334413; 7744225
Drug dependenceProtein kinase C delta typeQ05655T448618817100; 11334413; 7744225
HepatotoxicityCytochrome P450 3A4P08684T3784811170509; 11511170; 12399157
ObesityNAD-dependent protein deacetylase sirtuin-1Q96EB6T1473110900012; 15096598; 10585468
ObesitySterol regulatory element-binding protein 1P36956T4723610900012; 15096598; 10585468
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Alanine aminotransferase increased13.03.01.003--
Anaemia01.03.02.001--
Asthenia08.01.01.001--Not Available
Body temperature increased13.15.01.001--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Gastrointestinal pain07.01.05.005--
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.004--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Laboratory test abnormal13.18.01.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.006--Not Available
Shock24.06.02.002--Not Available
Syncope17.02.04.008; 24.06.02.012; 02.01.02.008--
Volume blood increased13.11.02.001--Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Idiosyncratic drug reaction08.06.01.002--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Ill-defined disorder08.01.03.049--Not Available
The 1th Page    1    Total 1 Pages